

YB1 -a Cancer Biomarker and a Drug Resistance Factor

Ahmad Hammoud, Chloe Bessiere, Emmanuelle Soleilhac, Fabienne Meggetto, Marie-Odile Fauvarque, Joanna Timmins, Fabienne Hans

▶ To cite this version:

Ahmad Hammoud, Chloe Bessiere, Emmanuelle Soleilhac, Fabienne Meggetto, Marie-Odile Fauvarque, et al.. YB1 -a Cancer Biomarker and a Drug Resistance Factor. 15th 3R meeting, May 2024, Leucate, France. hal-04902343

HAL Id: hal-04902343 https://hal.science/hal-04902343v1

Submitted on 20 Jan 2025

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Public Domain

YB1 – a Cancer Biomarker and a Drug Resistance Factor


Ahmad HAMMOUD¹, Chloe BESSIERE², Emmanuelle Soleilhac³, Fabienne MEGGETTO², Marie-Odile Fauvarque³, Joanna TIMMINS¹, Fabienne HANS¹

1. U5075, CNRS/CEA/UGA, I2SR Group, Institut de Biologie Structurale, 38000 Grenoble

2. U1037-Inserm/U5071-CNRS/Université Paul Sabatier | Centre de Recherches en Cancérologie de Toulouse (CRCT) | 2 Avenue Hubert Curien | 31037 Toulouse **3.** UA13, Inserm/CEA/UGA, Biosciences et bioingénierie pour la santé (BGE) IRIG/DRF




Introduction: Y-box binding protein 1 (YB1) is a member of the cold shock protein family, which is known for its DNA- and RNA-




Origin of the Project:

Our team has shown that YB1 interacts with NTH1 and stimulates its DNA repair activity [1]; NTH1 is a DNA repair enzyme of the base excision repair (BER). As shown in the figure, this interaction is enhanced in MCF7 breast cancerderived cells treated with first-line chemotherapeutic agents, such as cisplatin, leading to resistance to anticancer treatment.

[1] Senarisoy M, Barette C, Lacroix F, De Bonis S, Stelter M, Hans F, Kleman JP, Fauvarque MO, Timmins J. Förster Resonance Energy Transfer Based Biosensor for Targeting the hNTH1-YB1 Interface as a Potential Anticancer Drug Target. ACS *Chem Biol. 2020 15(4):990-1003.*



YB1 Domain Organisation



Objective:

This urged the team to evaluate the potential of YB1 as a key biomarker in cancer biology and to characterize its precise role in cancer progression, DNA repair and chemoresistance. Our first goal was to perform a bioinformatic analysis of public databases to identify cancer types overexpressing YB1 compared to the equivalent healthy tissue, showing a correlation between YB1 and BER factor expression, and having Yb1 as a potential factor for early diagnosis and prognosis.



Results: Bioinformatics Analysis


Ę

ug 0.4


0.0

A- YB1 mRNA Expression (TPM): Cancer vs Healthy

Cancerous Tissues (TCGA) vs Healthy Tissues (GTEx)




B- YB1 mRNA Expression and Early Diagnosis




Cancer tissues show an overall significant overexpression of YB1 compared to healthy tissues.

YB1 is significantly overexpressed in most cancer tissues. This profile supports the overexpression results observed in the cancer cell lines (in Panel 4).

Cancer Cell Lines (CCLE) vs Healthy Tissues (GTEx)






Cancer Name


this curve is used to determine Based on Panel2, YB1 could potentially be used as an early diagnostic the diagnostic potential of YB1. factor (1 > AUC > 0.7) in 8/15 cancer types.

C- YB1 mRNA Expression and Prognosis



D- Cancer Cell Lines Selection

Portals and Databases



- **CCLE:** Cancer Cell Line Encyclopedia (Cell lines data; Broad Institute)
- **TCGA:** The Cancer Genome Atlas (Patients data; National Cancer Institute and National Human Genome Research Institute)
- **GTEx:** Genotype-Tissue Expression (Healthy tissues data; Broad Institute)

Conclusions

- The over expression of YB1 (shown) and several BER factors (not shown) in patients (TCGA), supports our selection of the cell lines.
- YB1 is a potential diagnostic and prognostic factor in several cancer types.
- We will experimentally study the correlation between YB1 expression, DNA repair, and drug resistance in the selected cancer cell lines through different techniques like Western Blot, RTqPCR, siRNA Knockdown, drug sensitivity tests...etc.

Acknowledgements: We thank the CEA Focus Biomarker program for funding the thesis and Laurent Guyon (IRIG, CEA) for his advice in bioinformatics.





Grenoble Alliance for Integrated Structural & Cell Biology

Grenoble Alpes